Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is
synthetically manufactured from naturally occurring taxanes extracted from yew starting
material. The synthesis involves modification to the taxane side chain to overcome multidrug
resistance and to achieve mutant tubulin binding. This study will be a multi-center, dose
escalation, sequential group, Phase 1 study evaluating the intravenous administration of TPI
287 on an every 21 day cycle.